---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010540"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:50:22.994681+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apellis reports preliminary 2025 U.S. net product revenues of $689M; cash $466M; SYFOVRE injections up 17%

## Summary
- Full-year 2025 preliminary U.S. net product revenues: SYFOVRE $587M, EMPAVELI $102M, total $689M.
- SYFOVRE total injection demand grew 17% YoY; ~60% market share in geographic atrophy; prefilled syringe submission planned 1H 2026.
- EMPAVELI C3G/IC-MPGN launch: 267 patient start forms in 2025, >5% market penetration; 95% payer coverage.
- Cash and cash equivalents ~$466M at Dec 31, 2025; company expects to fund operations to profitability.
- Pivotal trials initiated for EMPAVELI in FSGS and DGF; IND for APL-9099 (FcRn) planned 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-010540
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312526010540/0001193125-26-010540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312526010540/d19666d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010540
- JSON: https://secwatch.observer/filing/0001193125-26-010540.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.